Durvalumab
Durvalumab (MEDI 4736) is a humanized monoclonal antibody targeting PD-L1. It can block the interaction of PD-L1 with PD-1 and CD80, with IC50 values of 0.1 and 0.04 nM, respectively. Durvalumab is often used in combination with platinum-based compounds for the treatment of non-small cell lung cancer and advanced hepatocellular carcinoma cells.
Product Specifications
Stability
≥ 2 years
Purity
>98% (HPLC)
Molecular Formula
——
Notes
Research use only, not for human use.
Receptor
PD-1/PD-L1
CAS Number
1428935-60-7
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS2147554-01 0.1 mL
APC-Linked Monoclonal Antibody to Myosin Heavy Chain 8, Skeletal Muscle, Perinatal (MYH8)
Ask
View Details MBS2147554-02 0.2 mL
APC-Linked Monoclonal Antibody to Myosin Heavy Chain 8, Skeletal Muscle, Perinatal (MYH8)
Ask
View Details 
MBS2147554-03 0.5 mL
APC-Linked Monoclonal Antibody to Myosin Heavy Chain 8, Skeletal Muscle, Perinatal (MYH8)
Ask
View Details 
MBS2147554-04 1 mL
APC-Linked Monoclonal Antibody to Myosin Heavy Chain 8, Skeletal Muscle, Perinatal (MYH8)
Ask
View Details MBS2147554-05 5 mL
APC-Linked Monoclonal Antibody to Myosin Heavy Chain 8, Skeletal Muscle, Perinatal (MYH8)
Ask
View Details